China SXT Pharmaceuticals Inc. [NASDAQ: SXTC] stock went on an upward path that rose over 41.33% on Friday, amounting to a one-week price increase of more than 57.04%. The company report on February 19, 2021 that China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split.
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”) announced that a 1 for 4 reverse split of its ordinary shares was approved by the Company’s board of directors on January 23, 2021 and is expected to become effective on February 19, 2021, China SXT’s ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on February 22, 2021.
Upon the effectiveness of the reverse share split, the Company’s shareholders will receive one new ordinary share of the Company for every four shares they hold. The Company’s ordinary shares is expected to begin trading on a split-adjusted basis when the market opens on February 22, 2021.
Over the last 12 months, SXTC stock rose by 20.32%.
The market cap for the stock reached $23.30 million, with 13.27 million shares outstanding and 11.96 million shares in the current float. Compared to the average trading volume of 240.07K shares, SXTC stock reached a trading volume of 113738407 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on China SXT Pharmaceuticals Inc. [SXTC]:
The Average True Range (ATR) for China SXT Pharmaceuticals Inc. is set at 0.16, with the Price to Sales ratio for SXTC stock in the period of the last 12 months amounting to 4.02. The Price to Book ratio for the last quarter was 1.51, with the Price to Cash per share for the same quarter was set at 0.95. Price to Free Cash Flow for SXTC in the course of the last twelve months was 8.96 with Quick ratio for the last quarter at 3.80.
SXTC Stock Performance Analysis:
China SXT Pharmaceuticals Inc. [SXTC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 57.04. With this latest performance, SXTC shares gained by 54.74% in over the last four-week period, additionally sinking by -16.26% over the last 6 months – not to mention a rise of 20.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SXTC stock in for the last two-week period is set at 76.62, with the RSI for the last a single of trading hit 82.12, and the three-weeks RSI is set at 71.16 for China SXT Pharmaceuticals Inc. [SXTC]. The present Moving Average for the last 50 days of trading for this stock 1.38, while it was recorded at 1.55 for the last single week of trading, and 1.66 for the last 200 days.
Insight into China SXT Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and China SXT Pharmaceuticals Inc. [SXTC] shares currently have an operating margin of -25.98 and a Gross Margin at +52.37. China SXT Pharmaceuticals Inc.’s Net Margin is presently recorded at -199.29.
Return on Total Capital for SXTC is now -9.77, given the latest momentum, and Return on Invested Capital for the company is -100.15. Return on Equity for this stock declined to -100.32, with Return on Assets sitting at -52.53. When it comes to the capital structure of this company, China SXT Pharmaceuticals Inc. [SXTC] has a Total Debt to Total Equity ratio set at 71.52. Additionally, SXTC Total Debt to Total Capital is recorded at 41.70, with Total Debt to Total Assets ending up at 30.98. Long-Term Debt to Equity for the company is recorded at 0.39, with the Long-Term Debt to Total Capital now at 0.23.
Reflecting on the efficiency of the workforce at the company, China SXT Pharmaceuticals Inc. [SXTC] managed to generate an average of -$106,061 per employee. Receivables Turnover for the company is 0.66 with a Total Asset Turnover recorded at a value of 0.26.China SXT Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 4.00.
China SXT Pharmaceuticals Inc. [SXTC] Insider Position Details
There are presently around $0 million, or 1.40% of SXTC stock, in the hands of institutional investors. The top three institutional holders of SXTC stocks are: HRT FINANCIAL LP with ownership of 95,500, which is approximately New of the company’s market cap and around 13.70% of the total institutional ownership; CITADEL ADVISORS LLC, holding 53,418 shares of the stock with an approximate value of $0.11 million in SXTC stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $56000.0 in SXTC stock with ownership of nearly 0% of the company’s market capitalization.
4 institutional holders increased their position in China SXT Pharmaceuticals Inc. [NASDAQ:SXTC] by around 175,951 shares. Additionally, 5 investors decreased positions by around 178,171 shares, while 1 investors held positions by with 143,006 shares. The mentioned changes placed institutional holdings at 211,116 shares, according to the latest SEC report filing. SXTC stock had 4 new institutional investments in for a total of 175,951 shares, while 4 institutional investors sold positions of 172,898 shares during the same period.